Skip to main content

Table 7 COX regression analysis of prognostic factors affecting PFS in SCLC ICIs-related myocarditis patients

From: Immune checkpoint inhibitor-related myocarditis in patients with lung cancer

Factors

Univariable

 

Multivariable

Hazard Ratio

(95% CI)

P Value

 

Hazard Ratio

(95% CI)

P Value

Age ≥ 70

0.8(0.21–2.8)

0.703

   

BMI ≥ 24

1.5(0.47–4.95)

0.489

   

Male

1.4(0.31–6.25)

0.675

   

Smoke

1.2(0.32–4.22)

0.824

   

Drink

0.8(0.26–2.29)

0.635

   

Extensive stage

22.5(0.001-376273.39)

0.530

   

PD1

1.5(0.49–4.71)

0.465

   

Cardiovascular history

1.5(0.47–4.48)

0.512

   

Diabetes Mellitus

0.3(0.04–2.49)

0.276

   

PD-L1 express

0.04(0-742.42)

0.530

   

Driving gene mutations

1.9(0.24–14.87)

0.551

   

History of radiotherapy

0.8(0.25–2.38)

0.660

   

Immunotherapy lines ≥ 2

2.0(0.62–6.57)

0.244

   

Concurrent other irAEs

1.1(0.35–3.28)

0.910

   

Glucocorticoids therapy

0.8(0.18–3.67)

0.787

   

immunotherapy cycles ≥ 2

0.1(0.04–0.50)

0.002

 

0.2(0.04–0.61)

0.007

Grade of myocarditis > 2

21.5(1.34–343.70)

0.030

 

6.4(0.37-109.32)

0.201

  1. BMI, body mass index; NSCLC, non-small cell lung cancer; PD-1, anti-programmed death-1; ICI, immune checkpoint inhibitors; irAEs, immune-related adverse events; PD-L1 express, anti-programmed death-ligand 1 express
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us